By Fineline Cube 
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today disclosed its intention to spin‑off and list its wholly‑owned subsidiary, Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd., on the Hong Kong Stock Exchange (HKEX).
About Fosun Adgenvax
Founded in July 2012, Fosun Adgenvax specialises in the research, development, manufacturing and sales of human vaccines. The company has built proprietary technology platforms for both bacterial and viral vaccines and holds a robust pipeline of licensed and investigational products.
Commercially Approved Products
| Product | Status (China) |
|---|---|
| Human Rabies Vaccine (Vero cell) | Approved for market launch |
| Freeze‑dried Human Rabies Vaccine (Vero cell) | Approved for market launch |
| Trivalent Influenza Split Vaccine | Approved for market launch |
| Quadrivalent Influenza Split Vaccine | Approved for market launch |
Clinical Development Portfolio
| Product | Category | Phase (China) |
|---|---|---|
| 13‑valent Pneumococcal Conjugate Vaccine | Conjugate | Phase III |
| Freeze‑dried Human Rabies Vaccine (Human Diploid Cell) | Rabies | Phase I |
| 24‑valent Pneumococcal Polysaccharide Conjugate Vaccine | Polysaccharide | Phase I |
| 23‑valent Pneumococcal Polysaccharide Vaccine | Polysaccharide | Approved for clinical trial |
Strategic Rationale
The proposed HK listing is expected to:
- Provide a dedicated capital‑market vehicle for Fosun Adgenvax’s future growth.
- Enhance visibility and access to international investors.
- Accelerate commercialization of its vaccine pipeline.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech